Immediate neurological recovery following perispinal etanercept years after brain injury

Clinical Drug Investigation

Volumn 34, Issue 5, 2014, Pages 361-366

  Tobinick, Edward ^a   Rodriguez Romanacce, Helen ^a   Levine, Arthur ^a   Ignatowski, Tracey A ^b   Spengler, Robert N ^c  

^a Institute of Neurological Recovery   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c School of Medicine and Biomedical Sciences University at Buffalo State University of New York ^*

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; APRAXIA OF SPEECH; ARTICLE; ATAXIC APHASIA; BRAIN INJURY; BRAIN LEVEL; CASE REPORT; CELL ACTIVATION; CONVALESCENCE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMIPARESIS; HUMAN; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; PATHOGENESIS; PERISPINAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BRAIN INJURIES; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN INJURIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899495666     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0186-1     Document Type: Article

References (45)

1. Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology. 2000;55(7):1052-4.
2. Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int. 2004;146(2-3):97-104. (Pubitemid 39470145)
3. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005;24(2):591-5. (Pubitemid 41359057)
4. Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD, Lammertsma AA, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med Off Publ Soc Nucl Med. 2011;52(8):1235-9.
5. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374-83.
6. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(Pt 1):28-42.
7. Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145-55.
8. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, Depuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051-70.
9. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6(2):67-72. (Pubitemid 32606886)
10. Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115(4):921-9.
11. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7(7):e40065.
12. Patterson J. F-A-S test. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York: Springer Science + Business Media; 2011. p. 1024.
13. Gagnon C, Mathieu J, Desrosiers J. Standardized finger-nose test validity for coordination assessment in an ataxic disorder. Can J Neurol Sci Le J Can Sci Neurol. 2004;31(4):484-9. (Pubitemid 39587194)
14. Lanzino DJ, Conner MN, Goodman KA, Kremer KH, Petkus MT, Hollman JH. Values for timed limb coordination tests in a sample of healthy older adults. Age Ageing. 2012;41(6):803-7.
15. Numasawa T, Ono A, Wada K, Yamasaki Y, Yokoyama T, Aburakawa S, et al. Simple foot tapping test as a quantitative objective assessment of cervical myelopathy. Spine. 2012;37(2):108-13.
16. Ross TP, Calhoun E, Cox T, Wenner C, Kono W, Pleasant M. The reliability and validity of qualitative scores for the Controlled Oral Word Association Test. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 2007;22(4):475-88. (Pubitemid 46810184)
17. Harkonen R, Harju R, Alaranta H. Accuracy of the Jamar dynamometer. J Hand Ther Off J Am Soc Hand Ther. 1993;6(4):259-62.
18. Longwell T, Truax P. The differential effects of weekly, monthly, and bimonthly administration of the beck depression inventory-II: psychometric properties and clinical implications. Behav Ther. 2005;36:265-75.
19. King NS, Crawford S, Wenden FJ, Moss NE, Wade DT. The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability. J Neurol. 1995;242(9):587-92.
20. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000;12(7):2623-33. (Pubitemid 30497055)
21. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Currents. 2014;14(1 Suppl):3-7.
22. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31-40.
23. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol. 2001;63(2):125-49.
24. Plata-Salaman CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE, et al. Kindling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol Brain Res. 2000;75(2):248-58. (Pubitemid 30109275)
25. Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis. 2004;16(2):321-34. (Pubitemid 38757314)
26. Mraovitch S, Calando Y, Regnier A, Lamproglou I, Vicaut E. Post-seizures amygdaloallocortical microvascular lesion leading to atrophy and memory impairment. Neurobiol Dis. 2005;19(3):479-89. (Pubitemid 40968061)
27. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflam. 2008;5:2.
28. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008;8:27.
29. Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009;14(3-4):168-77.
30. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs. 2009;23(9):713-25.
31. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985-1002.
32. Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):99-109.
33. Tobinick E. The cerebrospinal venous system: anatomy, physiology, and clinical implications. Med Gen Med. 2006;8(1):53.
34. Nathoo N, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007-14 (discussion 14).
35. Vox F, Capron AM, Kraus MF, Alexander GC, Kirschner KL. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R J Inj Funct Rehabil. 2013;5(10):882-9.
36. Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11(1):121-39.
37. Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, et al. Documentation of off-label use of biologics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii35-51.
38. Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53(1):71-104. (Pubitemid 28204679)
39. Guidance for off-label use of drugs. Lancet Neurol. 2008;7(4):285.
40. Committee on Drugs. Policy statement: off-label use of drugs in children. Pediatrics. 2014;133:563-7.
41. Horrobin DF. Effective clinical innovation: an ethical imperative. Lancet. 2002;359(9320):1857-8. (Pubitemid 34607066)
42. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-2.
43. American Psychiatric Association. The principles of medical ethics with annotations especially applicable to psychiatry. 2001st ed. Washington: American Psychiatric Association; 2001. p. 46.
44. Ghaemi SN, Goodwin FK. The ethics of clinical innovation in psychopharmacology: challenging traditional bioethics. Philos Ethics Humanit Med. 2007;2:26.
45. Gray H, Holmes T. Anatomy, descriptive and surgical. 4th ed. London: Longmans, Green, and Co.; 1866.